Rigel Pharmaceuticals, Inc.
RIGL · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $69 | $102 | $53 | $58 |
| % Growth | -31.7% | 90.7% | -7.4% | – |
| Cost of Goods Sold | $5 | $5 | $4 | $6 |
| Gross Profit | $65 | $97 | $49 | $52 |
| % Margin | 93.2% | 95.6% | 91.7% | 89.9% |
| R&D Expenses | $7 | $7 | $8 | $6 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $29 | $29 | $28 | $30 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $36 | $36 | $36 | $35 |
| Operating Income | $28 | $61 | $13 | $17 |
| % Margin | 40.9% | 60.1% | 23.9% | 28.9% |
| Other Income/Exp. Net | -$1 | -$1 | -$1 | -$1 |
| Pre-Tax Income | $28 | $60 | $12 | $15 |
| Tax Expense | -$0 | $0 | $0 | $1 |
| Net Income | $28 | $60 | $11 | $14 |
| % Margin | 40.2% | 58.6% | 21.5% | 24.9% |
| EPS | 1.547 | 3.33 | 0.64 | 0.81 |
| % Growth | -53.6% | 420.3% | -21% | – |
| EPS Diluted | 1.457 | 3.28 | 0.63 | 0.8 |
| Weighted Avg Shares Out | 18 | 18 | 18 | 18 |
| Weighted Avg Shares Out Dil | 19 | 18 | 18 | 18 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $1 | $1 |
| Interest Expense | $2 | $2 | $2 | $2 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | $30 | $62 | $14 | $18 |
| % Margin | 43.4% | 61.4% | 26.2% | 30.9% |